Keyword: Exosome Diagnostics
Bio-Techne’s urine test has received a breakthrough device designation from the FDA for ruling out unnecessary tissue biopsies.
Bio-Techne will pay up to $575 million to acquire liquid biopsy player Exosome Diagnostics.
The 18-month study will assess whether Vectra DA delivers better outcomes and lower costs than conventional approaches.
Liquid biopsy player Exosome Diagnostics is partnering with CareFirst to create evidence development studies for the evaluation of its EvoDx tests.
Earlier this year, Exosome Diagnostics said that it would scout out deals with biopharma partners to gain ground with its liquid biopsy tests. Now, the company is delivering on this goal by partnering with biotech titan Amgen.